Biotech Nintx Secures US$ 10 Million To Develop Medicines From Brazilian Biodiversity | |
Nintx (Next Innovative Therapeutics), a biotech company focused on developing treatments for multifactorial diseases using Brazil’s biodiversity, has raised an additional US$ 10 million following a US$ 3 million seed investment in 2022. The funds will support the company’s R&D of eight new drug programs, partnerships with companies like Adeste and Centroflora, and research institutions such as CIEnP and CNPEM. Nintx utilizes proprietary technologies, including xGIbiomics® to simulate the gastrointestinal system and GAIApath®, a data analytics platform mapping connections between plants, natural products, biological targets, the human microbiome, and multifactorial diseases. The company’s business model involves advancing therapies through preclinical studies and licensing them to pharmaceutical companies for clinical development. Nintx expects to license its first drug candidate within three years. Investors in the Series A round include Pitanga, Ecoa Capital, MOV Investimentos, and strategic partners Tiaraju and Adeste. Additionally, the company received a US$ 2.5 million grant from FINEP, a public entity promoting innovation. For more details please visit our website - https://www.medhealthinsight.com/biotech-nintx-secures-us-10-million-to-develop-medicines-from-brazilian-biodiversity/ ![]() | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: New York Target City : New York City Last Update : Jul 29, 2025 2:45 AM Number of Views: 14 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |